We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Noble Life Sciences Partners with BioFactura
News

Noble Life Sciences Partners with BioFactura

Noble Life Sciences Partners with BioFactura
News

Noble Life Sciences Partners with BioFactura

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Noble Life Sciences Partners with BioFactura"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Noble Life Sciences, Inc. has announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biological.

The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs.

Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.

BioFactura’s capabilities enable rapid, scalable, high potency production of protein drug candidates in mammalian and microbial systems, from development of expression vectors and cell lines to growth medium optimization, protein purification, and process scale-up.

BioFactura’s StableFast™ biomanufacturing platform is a unique, patented system for developing stable mammalian NS0 cell lines that can generate over one gram of protein in eight weeks.

“This relationship allows Noble to offer end-to-end preclinical biopharmaceutical development services - from cell line development to protein production, in vitro screening, in vivo efficacy and pharmacodynamics testing and biomarker development” said Alain Cappeluti, Noble Life Sciences President.

“We are looking forward to working with Noble to provide drug developers wider access to our unique capabilities,” said Darryl Sampey, BioFactura’s President and CEO.

Sampey continued, “This partnership creates an excellent synergy between Noble’s experienced scientific drug development team and BioFactura’s protein bioprocessing expertise.”

Advertisement